检验医学与临床2024，Vol.21Issue(7)：912-917,6.DOI:10.3969/j.issn.1672-9455.2024.07.011
新型冠状病毒奥密克戎变异株感染老年患者的临床特征分析
Analysis of clinical characteristics of elderly patients with SARS-CoV-2 Omicron variant infection
摘要
Abstract
Objective To analyze the clinical characteristics of elderly patients with Omicron variant infec-tion.Methods The clinical data of 516 elderly patients with Omicron variant infection admitted and treated in this hospital from October 2022 to January 2023 were collected and analyzed.The diagnosis and classification were performed by referring to the"Diagnosis and Treatment Protocol of COVID-19(Trial implementation of the 10th edition)".Results Among 516 elderly patients,56 cases were mild,256 cases were moderate,94 ca-ses were severe and 110 cases were the critical type.The proportion of WBC count decrease,neutrophil count increase,lymphocytes percentage decrease,CRP increase,myoglobin increase and BUN increase in laboratory tests in the elderly patients with medium,heavy and critical type infection had statistical differences when compared to the patients with mild type infection(P＜0.05).The changes of chest CT in elderly patients were mainly in both lungs(81.40％),which were mainly ground glass shadow(94.52％),patchy(77.62％)and paving stone(32.38％).Among 516 cases,439 cases survived and 77 cases died.The multifactorial Logis-tic analysis showed that the advanced age,lymphocyte percentage decrease,myoglobin increase,D-dimer in-crease and procalcitonin increase were the independent risk factors of the death in elderly patients with infec-tion(P＜0.05).Conclusion Age,lymphocytes percentage,myoglobin,D-dimer and procalcitonin have the close association with the death in elderly patients with infection关键词
新型冠状病毒/奥密克戎变异株/淋巴细胞百分比/肌红蛋白/D-二聚体/降钙素原/临床特征Key words
SARS-CoV-2/Omicron variant/lymphocytes percentage/myoglobin/D-dimer/pro-calcitonin/clinical characteristics分类
医药卫生引用本文复制引用
黄梦婷,杨守红,刘瑞雪,何菲..新型冠状病毒奥密克戎变异株感染老年患者的临床特征分析[J].检验医学与临床,2024,21(7):912-917,6.基金项目
重庆市科卫联合医学科研项目(2022MSXM177) （2022MSXM177）
重庆市永川区科技局技术创新与应用发展专项(2021yc-cxfz30017). （2021yc-cxfz30017）
